Status:
COMPLETED
CP-690,550 And Oral Contraception Drug-Drug Interaction Study
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
FEMALE
18-55 years
Phase:
PHASE1
Brief Summary
This study is designed to assess whether co-administration of CP-690,550 and oral contraceptives will effect the metabolism of the oral contraceptives in healthy volunteers.
Eligibility Criteria
Inclusion
- Healthy female subjects
- No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis
Exclusion
- Any medical reason which would contraindicate the administration of oral contraceptives
- Clinically significant infections within the past 3 months or history of febrile illness within 5 days
- Positive screening test for Hepatitis B surface antigen, anti Hepatitis C antibody, or human immunodeficiency virus
- Pregnant or nursing women, and women of childbearing potential who are unwilling or unable to use an acceptable method of nonhormonal contraception
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01137708
Start Date
June 1 2010
End Date
July 1 2010
Last Update
August 6 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, B-1070